Gurpreet Ahluwalia, MD
Psychiatry · San Diego, CANPI 1164452272
Payments from drug & device makers
Across 227 payments — averaging $34.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Alkermes, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$949
- Otsuka Pharmaceutical Development & Commercialization, Inc.$117
- W. L. Gore & Associates, Inc.$67
- plus $14 from 1 others
What the payments were for
- Travel & lodging$140%
- Food & beverage$7,68999%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 79 | $2,623 |
| Alkermes, Inc. | 53 | $2,027 |
| Neurocrine Biosciences, Inc. | 68 | $1,934 |
| Otsuka America Pharmaceutical, Inc. | 24 | $949 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $117 |
| W. L. Gore & Associates, Inc. | 1 | $67 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$3,296
- LYBALVI$2,377
- INGREZZA$1,139
- ARISTADA INITIO$824
- CAPLYTA$821
- REXULTI$488
- ABILIFY MAINTENA$233
- ABILIFY ASIMTUFII$233
How this compares
$7,731 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $206,347 |
| Abilify MaintenaAripiprazole | 52 | $130,543 |
| Invega SustennaPaliperidone Palmitate | 27 | $83,662 |
| CaplytaLumateperone Tosylate | 47 | $76,693 |
| Abilify AsimtufiiAripiprazole | 13 | $62,215 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $25,829 |
| Lurasidone Hcl | 29 | $6,082 |
| Aripiprazole | 40 | $4,231 |
| Quetiapine Fumarate | 85 | $1,328 |
| Haloperidol Decanoate | 17 | $1,264 |
| Trazodone Hcl | 75 | $1,128 |
| Fluphenazine Decanoate | 16 | $1,114 |
| Bupropion XlBupropion Hcl | 66 | $910 |
| Olanzapine | 69 | $890 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,934 | $206,34727 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii | $949 | $192,75865 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,623 | $76,69347 claims |
| Alkermes, Inc.Lybalvi | $2,027 | $25,82917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in San Diego
- Eric ChavezSan Diego$15.5M
- Charmaine SemeniukSan Diego$8.9M
- Jonathan MeyerSan Diego$2.3M
- Vishaal MehraSan Diego$1M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.